BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27599459)

  • 1. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
    Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
    J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
    Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
    Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
    Horton TM; Whitlock JA; Lu X; O'Brien MM; Borowitz MJ; Devidas M; Raetz EA; Brown PA; Carroll WL; Hunger SP
    Br J Haematol; 2019 Jul; 186(2):274-285. PubMed ID: 30957229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
    Kaspers GJL; Niewerth D; Wilhelm BAJ; Scholte-van Houtem P; Lopez-Yurda M; Berkhof J; Cloos J; de Haas V; Mathôt RA; Attarbaschi A; Baruchel A; de Bont ES; Fagioli F; Rössig C; Klingebiel T; De Moerloose B; Nelken B; Palumbo G; Reinhardt D; Rohrlich PS; Simon P; von Stackelberg A; Zwaan CM
    Br J Haematol; 2018 May; 181(4):523-527. PubMed ID: 29676440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
    Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
    Besse L; Besse A; Kraus M; Maurits E; Overkleeft HS; Bornhauser B; Bourquin JP; Driessen C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
    Szczepanek J; Pogorzala M; Konatkowska B; Juraszewska E; Badowska W; Olejnik I; Kuzmicz M; Stanczak E; Malinowska I; Stefaniak J; Sobol G; Szczepanski T; Czyzewski K; Wysocki M; Styczynski J
    Anticancer Res; 2010 Jun; 30(6):2119-24. PubMed ID: 20651360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
    Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
    Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Immuno)proteasomes as therapeutic target in acute leukemia.
    Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
    Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
    Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of bortezomib in refractory or relapsed acute leukemias.
    Cortes J; Thomas D; Koller C; Giles F; Estey E; Faderl S; Garcia-Manero G; McConkey D; Ruiz SL; Guerciolini R; Wright J; Kantarjian H
    Clin Cancer Res; 2004 May; 10(10):3371-6. PubMed ID: 15161691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the proteasome in AML.
    Csizmar CM; Kim DH; Sachs Z
    Blood Cancer J; 2016 Dec; 6(12):e503. PubMed ID: 27911437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
    Matondo M; Bousquet-Dubouch MP; Gallay N; Uttenweiler-Joseph S; Recher C; Payrastre B; Manenti S; Monsarrat B; Burlet-Schiltz O
    Leuk Res; 2010 Apr; 34(4):498-506. PubMed ID: 19811823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.